TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Ability of L-carnitine to Prevent Heart Damage in Breast Cancer Patients Receiving Anthracycline Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Female patients must have histologically or cytologically indicated breast cancer (stages I, II, III) eligible for adjuvant anthracycline chemotherapy \[FEC100 or AC-Taxol(paclitaxel) every 21 days.~* HER2 negative or HER2 positive breast cancer by immunohistochemistry (IHC3+) and/or fluorescent in-situ hybridization.~* Eastern cooperative oncology group (ECOG) performance status = 0, 1, 2~* Age ≥ 18 years old.~* Ability to understand and the willingness to sign a written informed consent document.~* The effects of L-carnitine on the developing human fetus at the recommended therapeutic dose are unknown. For this reason, women of child-bearing potential must agree to use adequate contraception prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.~Exclusion Criteria:~* Patients with evidence of metastatic breast cancer.~* Resting LV ejection fraction \< 50%.~* Patients having received previous anthracycline therapy or contraindication to anthracycline.~* Patients having a contraindication to L-carnitine therapy~* Dexrazoxane therapy at the time of enrollment.~* Patients with abnormal baseline bloodwork:~  * hemoglobin ≤ 100 mg/L~ * platelets ≤ 100 x 10\^9/L~ * white blood cells ≤ 4 x 10\^9/L~ * creatinine, AST, ALT, bilirubin \> 1.5 x the upper normal limits~* Participation in another randomized clinical trial.~* Patients having significant cardiac disease (previous myocardial infarction, congestive heart failure, or hemodynamically significant valvular heart disease) that would limit compliance with study requirements.~* Patients taking medication that may affect LV function (b-blockers, amiodarone, ACE-inhibitors, calcium channel blockers, or digoxin).~* Patients with symptoms of heart failure.~* Patients unable to participate in a study requiring long term follow up.~* Pregnant or lactating women.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: THromboprophylaxis In Sickle Cell Disease With Central Venous Catheters (THIS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult (age 18 or older)~2. Documented SCD~3. New or pre-existing CVC planned for long term use (at least 6 months)~4. Able to provide written consent~Exclusion Criteria:~1. Contra-indication to prophylactic dose anticoagulation or active bleeding at discretion of treating physician~2. Already on anticoagulation (prophylactic or therapeutic dose) for an indication other than CVC thromboprophylaxis~3. Previous VTE within the past 3 months~4. Pregnant, within 6 weeks post-partum, or active breast feeding~5. Creatinine clearance \<30mL/min (as calculated by Cockcroft-Gault equation\[67\])~6. Acute hepatitis or chronic active hepatitis~7. Cirrhosis with Child-Pugh score B or C~8. Platelet count \< 50 x109/L~9. Weight \<40kg~10. Uncontrolled HTN (systolic blood pressure \> 170mmhg, or diastolic blood pressure\> 100mmhg) despite antihypertensive treatment~11. On palliative care~12. On dual antiplatelet therapy, or high dose single agent aspirin \> 325mg/day~13. On combined P-glycoprotein and strong cytochrome P450 3A4 inhibitors (including but not limited to ketoconazole and protease inhibitors)~14. On combined P-glycoprotein and strong cytochrome P450 3A4 inducers (including but not limited to rifampin, phenytoin, phenobarbital, carbamazepine, and st. john's wort)~15. Active cancer or treatment for cancer excluding basal cell carcinoma~16. Known allergy to study drug~17. Strong indication for thromboprophylaxis at discretion of treating physician~18. Significant medical condition that confers an unacceptable risk to participating in the study, and/or that could confound the interpretation of the study data.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rivaroxaban thromboprophylaxis (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Abdominal Pain Disorders Functional in Children: Impact of Hypno-analgesia on the Autonomic Balance

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Parents affiliates or entitled to a social security scheme~* Consent form signed by the holder of parental authority~Exclusion Criteria:~* Child with pathologies reaching the central nervous system or the brain stem.~* Children with a severe pathology of cardio-respiratory or heart being referred to treatment.~* Children requiring emergency surgery or trauma or septic or inflammatory context.~* Children with psychiatric disorders or mental retardation proven.~* Children who have already used the earlier hypnosis.~* Children not speaking French language.

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of a Computerized Intervention for Learning to Re-Evaluate Suicidal Thoughts

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Suicidal ideation during the past two-weeks~Exclusion Criteria:~* Imminent risk for attempting suicide, requiring hospitalization~* Unmedicated psychotic spectrum or bipolar disorders

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Re-Evaluating Suicidal Thoughts (Type: EXPERIMENTAL): Participants in this condition will complete the experimental intervention at the baseline appointment.
- Healthy Social Living (Type: SHAM_COMPARATOR): Participants in this condition will complete the sham control intervention at the baseline appointment, and given the option to complete the experimental intervention at the conclusion of the follow-up period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Hydroxychloroquine In Covid-19 Kinetics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Symptoms occurring within 3 days prior to patient presenting to USA Facility for PCR nasopharyngeal swab~* Nasopharyngeal swab positive for Covid-19 infection and/or exposure and/or symptoms congruent with fever and cough~* Male or Female age 19 to 89 years~* Able to take oral medications~* Patients not requiring hospitalization~* Provision of informed consent~Exclusion Criteria:~* Known history of EKG QTc prolongation abnormality~* Contraindication or allergy to hydroxychloroquine~* Retinal eye disease~* Known glucose-6 phosphate dehydrogenase (G-6-PD) deficiency~* Known chronic kidney disease, stage 4 or 5 or receiving dialysis~* Weight \< 40 kg~* Current use of: hydroxychloroquine or cardiac medicines of: flecainide, Tambocor; amiodarone, Cordarone, Pacerone; digoxin or Digox, Digitek, Lanoxin; procainamide or Procan, Procanbid, propafenone, Rythmal)~* Known hepatic disease (cirrhosis, hepatitis)~* Active treatment for cancer (chemotherapy, radiation, surgery within 3 months~* On immunosuppressive drugs steroids, antirejection medications.~* Recipient of solid organ transplant~* Pregnancy/breastfeeding~* Past medical history Porphyria (may exacerbate disease)~* PMH Psoariasis (can worsen disease)~* No access to internet or email~* Current suicidal thoughts according to Columbia scale~* In the screening process before signing consent, subjects will be asked if they are suicidal. If this response is yes, patients will be excluded from trial and directed to the National Suicide Prevention Lifeline: 1-800-273-8255.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Hydroxychloroquine (Type: EXPERIMENTAL): Subjects in this arm will receive the study drug
- Placebo (Type: PLACEBO_COMPARATOR): Subjects in this arm will take placebo for 6 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Intensive Versus Regular Dosage For PD In AKI.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age older than 14 years;~* Be diagnosed as AKI according to KDIGO recommendation;~* Having indications for renal replacement therapy.~Exclusion Criteria:~* Having contraindications to peritoneal dialysis;~* Functional azotemia;~* Hypercatabolic status;~* Previous CKD history (baseline eGFR\<60ml/min/1.73m2 or proteinuria);~* Psychological disorder or communication barrier;~* Pregnancy;~* Refusing to receive dialysis therapy.~* receiving mechanical ventilation.

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention group (Type: EXPERIMENTAL): Intervention group is intensive dosage of PD.
- Control group (Type: ACTIVE_COMPARATOR): Control group is regular dosage of PD.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Levocetirizine on Inflammatory Mediators in Dermatographism

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CROSSOVER
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Patients with symptomatic dermatographism and chronic idiopathic urticaria.~2. Adult male and female between 18 to 60 years of age.~3. Signature of informed consent.~4. No known hypersensitivity to levocetirizine or to any of the ingredients of Xyzal® or to cetirizine.~5. Willingness to refrain from other antihistamines, prescription and and over- the-counter cough \& cold medications, topical creams, topical steroids and topical immunomodulators, for one week prior to the study. In very severe cases of CIU and dermatographism, based on dermatologist consultation and recommendation, and depending on the half-life of the prior antihistamine medication used, this period may be reduced to 3-4 three days. Rescue medication will be promptly provided if at any time the subjects will experience a significant relapse of their CIU symptoms.~6. Good general health.~7. Ability to understand and comply with the protocol.~8. Females of child-bearing potential must have a negative urine pregnancy test prior to randomization.~9. Absence of another active skin disease that may influence skin evaluation during the study.~Exclusion Criteria:~1. Pregnant females, females planning on getting pregnant or breast feeding.~2. Uncontrolled chronic disease such as diabetes.~3. The presence of renal disease with a moderate or severe renal impairment (since Xyzal is primarily eliminated through the kidneys) as documented from medical records or patient history.~4. History of anaphylaxis, angioedema or allergy to Xyzal or cetirizine (Zyrtec).~5. Any systemic disease involving mast cells such as allergic rhinitis, lung disease, asthma or autoimmune collagen disease.~6. Severe vascular or neurological diseases that would impart an asymmetric blood perfusion or an impaired function of the arms.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: None): Subjects with chronic idiopathic urticaria exhibiting dermatographism.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: EXPAREL Administered Into the TAP for Analgesia in Subjects Undergoing Open Total Abdominal Hysterectomy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Females, 18-75 years of age inclusive.~* American Society of Anesthesiologist (ASA) physical status 1-3.~* Undergoing open total abdominal hysterectomy (i.e., laparoscopic procedures are not sufficient) without any concurrent surgical procedure(s).~* Physically and mentally able to participate in the study and complete all study assessments.~* Able to give fully informed consent to participate in this study after demonstrating a good understanding of the risks and benefits of the TAP.~Exclusion Criteria:~* Demonstrated hypersensitivity or idiosyncratic reactions to amide-type local anesthetics.~* Any subject whose anatomy, or surgical procedure, in the opinion of the Investigator, might preclude the potential successful performance of a TAP.~* Any subject who in the opinion of the Investigator might be harmed or be a poor candidate for participation in the study.~* Any subject, who in the opinion of the Investigator, is on chronic pain medicine.~* Subjects who have received any investigational drug within 30 days prior to study drug administration, or planned administration of another investigational product or procedure during their participation in this study.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- EXPAREL Group 1 (Type: EXPERIMENTAL): EXPAREL 266 mg diluted with saline to a volume of 40 mL
- EXPAREL Group 2 (Type: EXPERIMENTAL): EXPAREL 266 mg diluted with saline to a volume of 60 mL

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: One-anastomosis Gastric Bypass/Mini-Gastric Bypass Versus Roux-en Y Gastric Bypass

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. primary obesity surgery and indication for gastric bypass~2. age: 18 - 65 years~3. BMI \> 40 kg/m² or BMI \> 35 kg/m² with obesity related comorbidities~4. informed consent~Exclusion Criteria:~1. obesity surgery in the anamnesis~2. visceral surgery in the anamnesis (excluding appendectomy and cholecystectomy)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- RYGB-group (Type: EXPERIMENTAL): Patients who undergo laparoscopic RYGB (150 cm alimentary limb, 50 cm biliopancreatic limb) as a primary surgery in obesity surgery; n = 50
- OAGB/MGB-group (Type: EXPERIMENTAL): Patients who undergo laparoscopic OAGB/MGB (200 cm biliopancreatic limb) as a primary surgery in obesity surgery; n = 50

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Benefits of ICD for the Primary Prevention in Patients With Valvular Cardiomyopathy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients who meet one of the following criteria:~  * Patients who have undergone surgery for aortic valve or mitral valve disease for more than 12 months~ * Patients with severe aortic valve or mitral valve disease~* Patients with left ventricular ejection fraction ≤ 35% by echocardiography or other imaging methods~* US, European practice guidelines class I indication for ICD implantation~* Patients without evidence of ischemic heart disease (who meet one of the following criteria):~  * Stress test negative~ * Significant stenosis was not observed in coronary artery images:~epicardial coronary stenosis \<70%, left main stenosis \<50%~* History of heart failure symptoms~* Patients who have received medication for more than 3 months according to the heart failure treatment guideline recommendation~Exclusion Criteria:~* Patients with left ventricular dysfunction without valvular heart disease~* Patients who require cardiac pacing therapy due to bradycardia~* Heart transplant scheduled~* Life expectancy is less than one year

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Valvular heart disease (Type: None): Patients with left ventricular dysfunction due to valvular heart disease who received ICD implantation for primary prevention of sudden cardiac death.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Different Electric Muscle Stimulation in Patients With Severe Sepsis and Respiratory Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* severe sepsis or septic shock patients with acute respiratory failure more than 3 days~* adult patients( age\>20 years-old)~Exclusion Criteria:~* skin wound/infection near the site of muscle stimulation~* acute myocardial infarction within 7 days~* pregnant women~* uncontrolled epilepsy~* no spontaneous breath because of central or cervical spinal neuropathy

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Biceps stimulation (Type: EXPERIMENTAL): EMS
- Quadriceps stimulation (Type: EXPERIMENTAL): EMS
- Control (Type: NO_INTERVENTION): Control group without electric muscle stimulation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Evacetrapib (LY2484595) in Japanese Participants With Primary Hypercholesterolemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Japanese outpatients who are diagnosed with primary hypercholesterolemia with LDL-C levels (measured by a direct method at baseline) that meet the following criteria. (Participant categories are based on the definition in Japan Atherosclerosis Society 2012 guidelines.)~  * Category I: 160 mg/deciliter (dL)≤LDL-C\<200 mg/dL~ * Category II: 140 mg/dL≤LDL-C\<175 mg/dL~ * Category III: 120 mg/dL≤LDL-C\<150 mg/dL~* Have triglycerides (TG) ≤400 mg/dL.~* Have HDL-C \<100 mg/dL.~Exclusion Criteria:~* Participants on LDL apheresis or plasma apheresis.~* Participants with secondary hypercholesterolemia or familial hypercholesterolemia.~* Any planned angiography. If angiography is planned, participants may be screened and enrolled after all such planned procedures are completed.~* History of any of the following any conditions:~  * Stable angina or acute coronary syndrome (unstable angina, myocardial infarction), old myocardial infarction or a coronary revascularization procedure including stent placement, or symptomatic carotid artery disease~ * peripheral arterial disease~ * ischemic stroke or transient ischemic attack (TIA)~ * intracranial hemorrhage~ * abdominal aortic aneurysm~* Have systolic blood pressure (SBP) \>160 millimeters of mercury (mm Hg) or diastolic blood pressure (DBP) \>100 mm Hg.~* Have a hemoglobin A1c ≥8.4% (National Glycohemoglobin Standardization Program).~* During the study period, participants who plan to use, are likely to require, or unwilling or unable to stop with adequate washout any prescription, over the counter medication, supplements or health foods with the intent to treat serum lipids (LDL-C, HDL-C, TG) including but not limited to these classes of drugs: statin, ezetimibe, bile acid sequestrant, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Participants taking probucol, fibrate or nicotinic agents within 8 weeks before screening are excluded from the study.~* Have been exposed to cholesteryl ester transfer protein inhibitors (e.g., anacetrapib or dalcetrapib).

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Evacetrapib (Type: EXPERIMENTAL): 130 milligrams (mg) evacetrapib given orally (PO) once a day for 12 weeks. Participants begin open label extension (130 mg evacetrapib given orally once a day for 40 weeks) after week 12.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo given PO once a day for 12 weeks. Participants begin open label extension (130 mg evacetrapib given PO once a day for 40 weeks) after week 12.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy